EUVIMEDEUVIMED entdecken
Crossref

Transforming rheumatoid arthritis care: dynamic budget impact models with ACR to DAS28 mapping for anti-TNFs, JAK inhibitors, and interleukins

Ahmed Al-Jedai, Hajer Al-Mudaiheem, Nayef Alghanim, Ibraheem Alhomood, Bedor Alomari, Fahad Alzuriqan, Khalidah Alonazi, Pratik Dhopte, Rita El Ojeil

Clinical Rheumatology · 2025

DOI: 10.1007/s10067-025-07644-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Rheumatology, 2025. Verfasst von Ahmed Al-Jedai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Alfaisal University, Colleges of Medicine and Pharmacy, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Janus Kinase Inhibitors, Tumor Necrosis Factor Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION/OBJECTIVES: Rheumatoid arthritis (RA) is a chronic autoimmune disease with substantial impacts on quality of life and healthcare systems. This study aimed to evaluate how the introduction of biologics and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) for managing moderate to severe RA in the Kingdom of Saudi Arabia (KSA) impacts efficacy, safety, and cost within the treatment pathway. METHOD: An Excel-based budget impact model was developed to estimate the financial consequences of adopting biologics and tsDMARDs from a payer perspective. It considered the direct treatment costs, cost offsets from reduced complications and hospitalizations, and the effect of managed-entry agreements (MEAs), assessed over 6-month cycles within a 5-year time horizon. Data inputs were derived from published literature, clinical guidelines, and a mapping technique used to correlate treatment efficacy across clinical trials. Sensitivity assessed the influence of varying parameters on the model outcomes. RESULTS: The introduction of biologics and tsDMARDs at different stages of the treatment pathway led to variable budget impacts ranging from -28% to + 79% from the base case (SAR 1,237 million) for low disease activity (LDA) and - 28% to + 86% from the base case (SAR 1,095 million) for remission as the outcome. Earlier adoption increased initial costs but showed potential for long-term savings. MEAs significantly reduced net costs (- 29% to + 65% for LDA; - 30% to + 71% for remission from the base case), enhancing affordability. These findings support the hypothesis that strategic use of these therapies and agreements influences overall financial outcomes. CONCLUSIONS: Integrating biologics and tsDMARDs, particularly through MEAs, can optimize RA treatment while managing costs. These results provide valuable insights for healthcare decision-makers in KSA, emphasizing the importance of cost-effective resource allocation. Key Points • A budget impact model was developed for Rheumatoid arthritis (RA) therapies in the Saudi healthcare context. • Managed-entry agreements (MEAs) reduce the net financial burden of newer RA treatments. • Early use of biologics and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) can offer long-term savings despite higher upfront costs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidAntirheumatic AgentsJanus Kinase InhibitorsTumor Necrosis Factor InhibitorsBiological ProductsHumansSaudi ArabiaBudgetsCost-Benefit AnalysisSeverity of Illness IndexModels, Economic

Stichwörter der Autor:innen

Disease-modifying antirheumatic drugsEconomic evaluationHealth care costsResource allocationRheumatoid arthritisSeverity of illness index

Substanzen

Antirheumatic AgentsJanus Kinase InhibitorsTumor Necrosis Factor InhibitorsBiological Products

Autor:innen und Institutionen

  • Alfaisal University, Colleges of Medicine and Pharmacy, Riyadh, Saudi Arabia.
  • Therapeutic Affairs, Ministry of Health, Riyadh, Saudi Arabia.
  • King Saud Medical City, Riyadh, Saudi Arabia.
  • King Fahad Medical City, Riyadh, Saudi Arabia.
  • Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
  • Drug Policy & Regulation Unit, Ministry of Health, Riyadh, Saudi Arabia.

Zitieren

APA

Al-Jedai, A., Al-Mudaiheem, H., Alghanim, N., Alhomood, I., Alomari, B., Alzuriqan, F., Alonazi, K., Dhopte, P., & Ojeil, R. E. (2025). Transforming rheumatoid arthritis care: dynamic budget impact models with ACR to DAS28 mapping for anti-TNFs, JAK inhibitors, and interleukins. Clinical Rheumatology. https://doi.org/10.1007/s10067-025-07644-0

Vancouver

Al-Jedai A, Al-Mudaiheem H, Alghanim N, Alhomood I, Alomari B, Alzuriqan F, et al. Transforming rheumatoid arthritis care: dynamic budget impact models with ACR to DAS28 mapping for anti-TNFs, JAK inhibitors, and interleukins. Clinical Rheumatology. 2025. doi:10.1007/s10067-025-07644-0

BibTeX
@article{AlJedai2025,
  author = {Al-Jedai, Ahmed and Al-Mudaiheem, Hajer and Alghanim, Nayef and Alhomood, Ibraheem and Alomari, Bedor and Alzuriqan, Fahad and Alonazi, Khalidah and Dhopte, Pratik and Ojeil, Rita El},
  title = {Transforming rheumatoid arthritis care: dynamic budget impact models with ACR to DAS28 mapping for anti-TNFs, JAK inhibitors, and interleukins},
  journal = {Clinical Rheumatology},
  year = {2025},
  doi = {10.1007/s10067-025-07644-0}
}
Kostenlos starten →